107
Participants
Start Date
September 5, 2011
Primary Completion Date
October 1, 2012
Study Completion Date
November 7, 2022
LGX818
Western Sydney Local Health District, Westmead
Westmead Hospital- Redbank Rd, Westmead
Peter MacCallum Cancer Centre, East Melbourne
Hospital Universitario Vall d'Hebron - PPDS, Barcelona
Universität Zürich, Zurich
Hospital Universitario HM Sanchinarro_CIOCC, Madrid
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC, Madrid
H Lee Moffitt Cancer Center and Research Institute, Tampa
Institut Gustave Roussy, Villejuif
Institut Gustave Roussy, Villejuif
Institut Gustave Roussy, Villejuif
Institut Gustave Roussy, Villejuif
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
EDOG - Institut Claudius Regaud - PPDS, Toulouse
National Cancer Center Hospital, Chuo-ku
Oslo Myeloma Center - PPDS, Oslo
Hospital Clinic de Barcelona, Badalona
Hospital General Vall d'Hebron, Barcelona
Hospital Universitario Vall d'Hebron - PPDS, Barcelona
Hospital Universitario Vall d'Hebron, Barcelona
Kantonsspital Graubünden, Chur
Lead Sponsor
Pfizer
INDUSTRY